R&D Pipeline

Glenmark’s R&D is committed to identifying products that fulfill unique and unmet medical needs in inflammation disorders, especially in respiratory and dermatology therapies and also oncology.

 


  Therapy Molecule MoA/Class Indication
Pre Clinical Phase 1 Phase 2 Phase 3 Approval
Specialty Respiratory Ryaltris™ - GSP 301 Steroid + AH Allergic Rhinitis
+
 
Respiratory
Specialty Respiratory GBR 310 Biosimilar Asthama,CIU
+
 
Respiratory
R&D Pipeline Respiratory GRC 39815 ROR γ t Inverse Agonist COPD
+
 
Respiratory
R&D Pipeline Pain GRC 17536 TRPA1 Inhibitor DPN
+
 
Pain